Literature DB >> 32484257

Vascularized composite allotransplantation in the United States: A retrospective analysis of the Organ Procurement and Transplantation Network data after 5 years of the Final Rule.

Holly C Lewis1, Linda C Cendales1.   

Abstract

On July 3, 2014, the Organ Procurement and Transplantation Network (OPTN) began overseeing vascularized composite allotransplantation/allografts (VCA) in the United States. For the past 6 years, centers performing VCAs have been requested to submit data into a biometric repository, in parallel with systems used by solid organ transplant centers. Currently, 62 VCAs are reported in the entire OPTN database, with 36 of these transplants reported as performed after VCA was added to the OPTN Final Rule. Of these 36 recipients, 16 received uterus transplants, most of which (11) occurred from living donors. Ten patients received hand transplants and 6 received face transplants. Two patients received abdominal wall transplants, 1 patient received a scalp transplant, and 1 patient received a penile transplant. The present manuscript represents the query of a nationalized database for VCA type, immunosuppression treatment, and clinical outcomes for VCAs. This manuscript provides a report of the current VCA data reported to the OPTN after the Final Rule.
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Organ Procurement and Transplantation Network (OPTN); United Network for Organ Sharing (UNOS); clinical research; health services and outcomes research; immunosuppressive regimens; vascularized composite allotransplantation

Mesh:

Year:  2020        PMID: 32484257     DOI: 10.1111/ajt.16086

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  1 in total

1.  TRFs and tiRNAs sequence in acute rejection for vascularized composite allotransplantation.

Authors:  Shengli Li; Jianda Zhou; Shoubao Wang; Yuan Fang; Haibo Li; Jingting Chen; Yao Xiong; Xu Li; Binbin Sun
Journal:  Sci Data       Date:  2022-09-07       Impact factor: 8.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.